A Possible Guide as a Tool to Complementary Effects of New Coronavirus

Sadremomtaz, Afsaneh; Hashemi, Javad; Sahebnasagh, Adeleh; Nabavi, Seyed Mohammad; Al-Dahmani, Zayana M; Gheibi, Shayesteh; Shahrami, Bita; Mosaed, Reza; Arfa, Peyman; Roshanzamiri, Soheil; Mojtahedzadeh, Mojtaba

doi:10.18502/aacc.v7i4.7633

Cited by 2 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, this biomarker plays a role in the resolution process by delaying the apoptosis of macrophages as well as reducing the secretion of interleukin-8 [4]. It is believed that a complex correlation exists between inflammatory and non-inflammatory mediators in several inflammatory and infectious diseases, including COVID-19 [5][6][7]. The data on the role of such mediators in COVID-19 and their exact roles in the treatment and prevention of the disease is still lacking.…”

Section: Introductionmentioning

confidence: 99%

Changes of LipoxinA₄ Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study

Jamali

Shahrami

Mojtahedzadeh

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

LipoxinA4 (LXA4) is an anti-inflammatory biomarker participating in the active process of inflammation resolution, which is suggested to be effective on infectious and inflammatory diseases like COVID-19. In this study, we hypothesized that LXA4 levels may increase following COVID-19 treatment and are even more accurate than commonly used inflammatory markers such as erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and ferritin. To test this hypothesis, a pilot study was conducted with 31 adult hospitalized patients with non-severe COVID-19. LXA4 levels were measured at the baseline and 48-72 hours later. Accordingly, ESR and CRP levels were collected on the first day of hospitalization. Moreover, the maximum serum ferritin levels were collected during the five days. LXA4 levels significantly increased at 48-72 hours compared to the baseline. ESR, CRP, and ferritin levels were positively correlated with the increased LXA4. In contrast, aging was shown to negatively correlate with the increased LXA4 levels. LXA4 may be known as a valuable marker to assess the treatment response among non-elderly patients with non-severe COVID-19. Furthermore, LXA4 could be considered as a potential treatment option under inflammatory conditions. Further studies are necessary to clarify LXA4 role in COVID-19 pathogenesis, as well as the balance between such pro-resolving mediators and inflammatory parameters.

show abstract

Section: Introductionmentioning

confidence: 99%

Changes of LipoxinA₄ Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study

Jamali

Shahrami

Mojtahedzadeh

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

LipoxinA4 as a Potential Prognostic Marker of COVID-19

et al. 2022

View full text Add to dashboard Cite

This pilot study aimed to determine early changes of LXA4 levels among the hospitalized patients confirmed as COVID-19 cases following the clinical management and its correlation with commonly used inflammatory markers, including erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and ferritin. Thirty-one adult hospitalized patients infected with the non-severe COVID-19 were included. LXA4 levels were measured at the baseline and 48-72 hours after hospitalization. Accordingly, ESR and CRP levels were collected on the first day of hospitalization. Moreover, the maximum serum ferritin levels were determined during the five days. LXA4 levels significantly increased at 48-72 hours compared to the baseline. ESR, CRP, and ferritin levels were positively correlated with the increased LXA4. In contrast, aging was shown to negatively correlate with the increased LXA4 levels. LXA4 may be known as a valuable marker to assess the treatment response among non-elderly patients with non-severe COVID-19. Furthermore, LXA4 could be considered as a potential treatment option under inflammatory conditions. Further studies are necessary to clarify LXA4 role in COVID-19 pathogenesis, as well as the balance between such pro-resolving mediators and inflammatory parameters.

show abstract

A Possible Guide as a Tool to Complementary Effects of New Coronavirus

Cited by 2 publications

References 51 publications

Changes of LipoxinA₄ Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study

Changes of LipoxinA₄ Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study

LipoxinA4 as a Potential Prognostic Marker of COVID-19

Contact Info

Product

Resources

About

A Possible Guide as a Tool to Complementary Effects of New Coronavirus

Cited by 2 publications

References 51 publications

Changes of LipoxinA4 Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study

Changes of LipoxinA4 Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study

LipoxinA4 as a Potential Prognostic Marker of COVID-19

Contact Info

Product

Resources

About

Changes of LipoxinA₄ Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study

Changes of LipoxinA₄ Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study